|
|
|
- きみお いしなみ
- 7 years ago
- Views:
Transcription
1
2
3
4
5
6
7 70% ADCA 28% SCA6 30% MJD 30% DRPLA 13% 20% SCA1 4% SCA2 3% RCA 2%
8
9
10
11
12
13
14
15
16
17
18 537 25
19
20
21 T2
22 C3 C6) LCL MRI
23 OB ph3 ph9
24
25 60/40/20mg/ 1000mg/ 3 500mg/ 6
26 1000mg/ 3 6/
27
28
29 %
30 / 24 (88%) 15 / 21 (71%) MS % 3 LCL: Long Cord Lesion 15 / 21 71% AQP4 1 2
31 MS Goodkin, D., et al.: Neurology 42: , 1992 Kurtzke, J. F.: Neurology 33: , 1983
32
33
34 MRI MRI CIS RRMS SPMS McDonald MS
35
36
37
38
39 β 2 β β β 3
40 4 APP)
41
42
43 5% 95% ε 5 6
44
45 7 n (n-3 PUFA) AD
46 8 β
47
48
49 9 10 Integrated treatment approach, Combination therapy
50
51
52
53 1 MRI
54
55
56
57 3 MIBG 4
58
59 3 MAO-B
60 4 7
61 4 a b 1 1 1
62
63
64
65 5 10
66
67
68
69
70
71
P1-1 P1-2 P1-3 P1-4 P1-5 P1-6 P3-1 P3-2 P3-3 P3-4 P3-5 P3-6 P5-1 P5-2 P5-3 P5-4 P5-5 P5-6 P7-1 P7-2 P7-3 P7-4 P7-5 P7-6 P9-1 P9-2 P9-3 P9-4 P9-5 P9-6 P11-1 P11-2 P11-3 P11-4 P13-1 P13-2 P13-3 P13-4 P13-5
( ) ー ( () ) 250 200 150 100 50 0 51 20 54 59 33 35 91 92 93 98 99 94 6 7 7 8 9 11 18 17 18 20 22 23 10 9 8 9 9 9 62 40 66 74 41 47 21 22 23 24 25 26 10 8 6 4 2 0 m3/s 7 41.3 5 5 18.4
124
[ ] [ ] 18 123 124 ( ) 125 126 127 128 5,683,062 2,306,419 18.2 14.0 12 5389 87 13 257 88 12 22 27 56.7 41.6 1 1.7 15 129 55 38.8 13.3 15 2004 15 1 3 84.8 29.3 1 23.9 38.0 10 10 35 35 15 5 56.5.31 55.4.1
Microsoft Word - 表紙資料２－４
(1) / 130 g 25 g 520% 170 g 30 g 560% 70 mg 600 mg 11.6% 0 10.5 mg 0% (1) (2) / 50100 g 25 g 200400% 50100 g 30 g 167333% 5001000 mg 600 mg 83167% 1020 mg 10.5 mg 95190% (2) / (1) 45.6 g 30 g 152% (2)
橡ファミリー企業の分析020806
2002 8 6 1 700 OB 2000 700 ( 40 ) 82 5 613 2 700 5,000 2 1,000 700 3 87 4,542 2,533 (82 5 ) 700 OB 405 ( ) 2,500 ( ) (660 40 ) 4 82 5 700 82 5 613 5 30 30 30 30 6 (2001 ) ( ) 1,174 1,023 113 1,136 100
4 5 Y40 706050 70 14 29 C 8 A 2 M 5 E 11 W D 2 60 24 40 C 8 A 3 M 14 E 7 W 3 D 4 Y 50 34 99 C 16 A 15 M 17 E 17 W 12 D 12 Y 6 K 4 11 3 14 21 3 23 22 20 12 17 10 5 15 5 21 3 42 11 8 OB 62 42 104 261
近畿中国四国農業研究センター研究報告 第７号
230 C B A D E 50m 558 0 1km (mg L 1 ) T N NO 2 3 N NH 4 N 2.0 0 (a) 2001 1.5 6 20 21 5 1.0 0.5 0.0 2.0 1.5 1.0 0.5 0.0 14:00 17:00 (b) 2001 7 3 4 20:00 23:00 2:00 (h) 5:00 8:00 11:00 10 0 5 10 15
12-7 12-7 12-7 12-7 12-8 12-10 12-10 12-10 12-11 12-12 12-12 12-14 12-15 12-17 12-18 10 12-19 12-20 12-20 12-21 12-22 12-22 12-23 12-25 12-26 12-26 12-29 12-30 12-30 12-31 12-33 12-34 12-3 12-35 12-36
- 1 -
19 21 - 1 - - 2 - - 3 - - 4 - 19 21 21 2224-5 - 19 2007 21 2009 H18 H27 18 27 10 H18 H22 18 22 22 H19 H21 19 21 21-6 - 20 21 19 2,449,254 2,495,506 1.9% 2,603,427 4.3% 1,593,428 1,582,704 0.7% 1,552,160
1 2 3 4 5 68g 9g 2g 0.2mg 0.8mg 316kcal 316cal 326kcal 326cal 6 010 3035 15 5355 30 120 20 7 8 9 10 11 () () () 12 1 3 1 5 1 80kcal 20 30 20 30 1 9 7.5 13 7.58.5 910.5 1213.5 11.512.5 14 15 79 23 1520
1 2
1 2 1 1pH WPC-Type25WPH-Type25F-Type N-Type 3 21997a 2 1997b 31997b 4 41 32008 42008 12008 42 5 4Uchino et al., 2003 51 2 3 12 4 8 16 5 6 LDH IgE Uchino et al., 2003 LDH 1 24 1 5120 39 52AD 5 AD NC/Nga
2009 Aida et al. Caries Res 2006;40 2000 100 % 78.7 88.0 96.6 98.8 98.8 98.8 100.0 100.0 100 75 69.4 50 75.3 74.8 73.3 73.1 73.0 72.4 71.8 71.7 51.7 40.2 69.4 68.8 73.6 25 22.3 32.8 21.9 22.9 22.1
13 13 13 13 M 1000 1001 1002 1003 1004 1005 12 54 67 12 133 5 14 1006 12 71 72 43 186 5 14 1007 1 1008 35-62-1 C 35--62-31 C 35-62-2 B 35-62-32 C 35-62-3 A 35-62-33 C 35-62-4 B 35-62-34 C 35-62-5 C 35-62-35
4 5 2 3 7 9 10 11 1 2 4 6 No.3709 5 9 10 3 1 9 10 11 11 1 4 6 No.3710 5 10 1 6 6 9 10
No.3707 5 2 29 30 1976 27 40 S K 40 30 8 9 9 11 ( ) No.3708 5 6 2 4 11 1 4 5 2 3 7 9 10 11 1 2 4 6 No.3709 5 9 10 3 1 9 10 11 11 1 4 6 No.3710 5 10 1 6 6 9 10 10 ( ) 1 No.3711 5 11 ( ) 7 9 10 11 11 1 2
NIHSS score p NIHSS score p149 4 p g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml
NIHSS score14 1 400 1 p149 1 25 20 NIHSS score14 15 10 5 2 p149 4 p151 0 0.8 g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml 1 2 148 149 3 2 3 A B C 4 D 2 A B C A C 1 Ogata T et al J Neurol Sci 272 83 86 2008
1 1 2 2 3 4 5 5 6 7 8 10 9 10 10 10 11 13 14 15 15 16 17 18 19 21 21 22 22 24 28 38 40 41 41 43 45 46 47 47 47 47 48 50 50 50 50 51 52 54 54 55 56 56 57 57 57 58 58 59 59 59 61 61 61 62 62 62 62 63 63
P15 P211 1 P1 P4 P2 P3 P4 P17
P15 P211 1 P1 P4 P2 P3 P4 P17 P3 P4 P7 P8 P9 2 1 Q A P17 P17 1 2 3 4 3 5 6 7 8 2 P17 Q A P17 4 1 2 3 4 2 P17 P4 P12 P17 P4 5 5 6 7 8 2 P4 P4 6 1 2 3 4 3 P17 P10 P17 7 5 6 7 8 4 0120-096-991 P17 8 1 2 3
150MHz 28 5 31 260MHz 24 25 28 5 31 24 28 5 31 1.... 1 1.1... 1 1.2... 1 1.3... 1 2.... 2 2.1... 2 2.2... 3 2.3... 7 2.4... 9 2.5... 11 3.... 12 3.1... 12 3.2... 13 3.3... 16 3.4... 24 4.... 32 4.1...
産衛誌57-4たより.indb
A89 26 7 1 9 4 33 1 87 A90 24 A91 23 ACOH2014 A92 4 1 2 3 4 5 6 7 A93 A94 A95 A96 A97 A98 A99 A100 A101 27 8 1 9 A102 4 33 A103 A104 26 3 140 27 1 A105 27 A106 A107 A108 A109 A110 A111 A112 A113 et al
江戸川区安全･安心まちづくり運動大綱
15 8 65 5 15 60 14 20.8 14 17,767 23 6,658 1,911 PTA - 1 - - 2 - ( - 3 - ( ) - 4 - ( ) ( ) () ( ) - 5 - PTA - 6 - ( ) ( ) - 7 - - 8 - 1 2 3 4 5-9 - 15 3 29 3,400 10 10 6000 14 4 346 15 6 30 100 15 13 720
,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,
1 1 1 2 1 3 1 4 2 5 5 6 6 1 6 2 7 3 7 4 7 5 7 7 8 8 10 1 10 2 10 3 10 12 1 12 2 12 3 12 4 13 5 14 14 1 14 1 2 3 4 5 1 2 3 4 16 5 16 6 16 7 17 6 17 18 19~23-19- 1 0.5 1 43.25 2.20 3.60 103.50 43.88 2.20
3 JAS JAS JAS 4
1 2 3 JAS JAS JAS 4 5 6 7 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 ph 102 106 K 31 32 13 3 15 79 33 34 35 36 37 20 6 H.22.3 http://www.caa.go.jp/foods/pdf/syokuhin19.pdf 38
肝臓病教室201207v2配布用.pptx
24 7 28 5 C C C C 11 1 vs 2 vs 1 0 1 600-1000mg 3-5/ 24,48 2448 12 1 1500-2250mg 6-9/ () 1 600-1000mg 3-5/ 0 24 88.1% 0 20 40 60 80 100 C ALT, GPT 30 34.4% ALT, GPT 0 20 40 60 80 100 2 , 2 3 1 1-100% 0
3 m/sec 8.35 39.06 3.22 2.15 13.72 52.78 15.00 2.12 2.69 12.62 27.62 3 m/ 772 79 68 263 410 1,182 3 m/sec 3.87 0.63 8.00 3.12 1.38 12.50 12.50 2.00 2.50 1.00 5.50 5.50 m/ 105 122 20 247 247 3 m/sec 0.23
表紙／１５１７０８Ｈ
! " # $ % & ' ( ) ! #! $! " % & " ' " # * + $ %, &! & ', '! " # $ (! " # $ )! " # $ !!$ "! " # $ #! " # $ $! " # $ %! " # $ ! " # " 1 $ 2 " $ % 3 & % ' ( 4 ( ) * ' + 5, -. 6 / 0 0 +, 1 -. 2 3 /! /!%!!
untitled
Y = Y () x i c C = i + c = ( x ) x π (x) π ( x ) = Y ( ){1 + ( x )}( 1 x ) Y ( )(1 + C ) ( 1 x) x π ( x) = 0 = ( x ) R R R R Y = (Y ) CS () CS ( ) = Y ( ) 0 ( Y ) dy Y ( ) A() * S( π ), S( CS) S( π ) =
スライド 1
e-japan -2004 1 Integrated Healthcare Network (IHN) e-icusentara Sentara Healthcare T C I H A H I 0 5 0 3 T C I H A H I 2 10 6 1 0 1935 40 45 50 55 60 65 70 75 80 85 90 95 2000 K. Matsuoka et al.
一般演題（ポスター）
6 5 13 : 00 14 : 00 A μ 13 : 00 14 : 00 A β β β 13 : 00 14 : 00 A 13 : 00 14 : 00 A 13 : 00 14 : 00 A β 13 : 00 14 : 00 A β 13 : 00 14 : 00 A 13 : 00 14 : 00 A β 13 : 00 14 : 00 A 13 : 00 14 : 00 A
: : 2001227 : 2
: : 2001227 : 2 mg/100gmg/100g mg/100g 3 10/102006 12/05 2/19, 2007 Zn 63 98 4 10% 5 Ramesh et al. 2004 6 Connoly et al. 2002 A IRT 7 8 2.11mg/100g143%56% 9 10 Alaria praelonga 11 2 12 13 14 15 16 1 1
平成25年度調理師試験問題
25 15 60 HB 2 1 1 2 36 1961 46 1971 56 1981 3 1991 3 4-1 - 5 6 7 8 6 2 12 31 1 15 1 15 4 15 4 15-2 - 9-3 - 10 11 12 13 3-4 - 14 腿 15 16 WHO 22 2010 17 18 1-5 - 19 1 g 4 kcal 4 kcal 9 kcal 9 kcal 20 21
untitled
20073-1- 3 4 5 9 12 14 17-2- 3,700ha 30,000t -3- 1t 70 50 40 C/N -4- 20011228 C/N 13 2001 2cm 1t 60 70 60-5- 70 1t -6- 2003131 ph EC T-C T-N C/N P2O5 K2O CaO MgO HO 2 ms % % % % % % % 8.52 0.64 74.9 44.9
M&A Brav et al.(2005) TOPIX Core30 4 TOPIX Core
1 2 ROE PBR 1 2 3 3.1 3.2 3.3 4 2006 1 2 1906 49.5 90 M&A Brav et al.(2005) 3 2 3 4 2006 1 TOPIX Core30 4 TOPIX Core30 30 5 3 18 12 14 5 4 http://www.tse.or.jp/topix/core30/index.html 5 2001 2005 5 30
untitled
82 83 84 5km 1897 8 3 85 86 87 PTA 88 89 90 91 92 14 93 94 2 95 11 H12 OB OB 96 H9.1.23 6 97 4.13.1 15 8 8 70 10 98 4.13.1 15 99 15 2 100 4.13.2 4.13.3 4.13.46 101 102 103 No. 1 A 14 15 2 A 42 3 A 3 133
20●12頁●６－１４▲放射線科▲.ppt
No.268 Katayama H. et al. Adverse reactions to ionic and nonionic contrast media-a report from the Japanese Committee of the Safety of Contrast Media. Radiology 1990;175:621-628. 12.66% 3.13% 0.22% 0.04%
! 1Munderl P et al. Survival and causes of death, 2 years after Introduction of antiretroviral therapy in Africa. XVI International AIDS Conference, 2006, Abstract THLB0208. 2Walensky RP et al. The
14 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 20 0 0 0 0 0 0 0 0 0 0 0 0 21 0 0 0 0 0 0 0 0 0 0 0 0 22 0 0 0 0 0 0 0 0 0 0 0 0 23 0 0 0 0 0 0 0 0 0 0 0 0 24 0 0 0 0 0 0 0 0 0 0 0 0 25 0 0 0 0 0 0 0 0 0
パーキンソン-本文修正済.indd
MIBG 107 LSI MIBG RI 1 SPECT MIBG 1 1 7 2-3-5 7 1-12 145 2215 1113-1-1 114 2713-1-30 5 7-1-1 6 9-1-1 401-1-11 131-2-50 10 2-15-1 2 1-2-54 43-1-1 2-10-10 1-10-1 2-1-1 1214-8 53 0166-22-8111 0166-51-3161
3228.pwd
1 2 1 P 2 P 1 3 4 5-1- 6 7 8 35 30 25 20 15 10 5 24 3 32 0-2- FAX -3- 28 25 12 2 5 12 0 5 10 15 20 25 30 46 38-4- -5-68 43 21 6 3 1 20 0 10 20 30 40 50 60 70 F F 900 1715 1,402 464 OB NPO 1000 1600 583
2.2 (1967) (1997,2003) 2.2 ( ) 11
( ) 2.1 10 2.2 (1967) (1997,2003) 2.2 ( ) 11 12 ( ) 90150 (684) (887) (1099) (1361) (1605) (1707) (1854) 21(1946) 8 2.3 (1854) 13 (1997) (1854.12.23) (M8.4) (24 ) (M8.4) 70,000 3000 ( ) 7 2 3 3 (,1997)
1 913 10301200 A B C D E F G H J K L M 1A1030 10 : 45 1A1045 11 : 00 1A1100 11 : 15 1A1115 11 : 30 1A1130 11 : 45 1A1145 12 : 00 1B1030 1B1045 1C1030
1 913 9001030 A B C D E F G H J K L M 9:00 1A0900 9:15 1A0915 9:30 1A0930 9:45 1A0945 10 : 00 1A1000 10 : 15 1B0900 1B0915 1B0930 1B0945 1B1000 1C0900 1C0915 1D0915 1C0930 1C0945 1C1000 1D0930 1D0945 1D1000
untitled
4 4 1 65 25 40 1987 1987 a 59 3 1987 b 4.1 62 63 65 1000 78 32 67 48 60 48 5 2 50 78 2 62 1 63 50 25 2 3 2 4.1.1 3 25 50 2 35 2 50 70 35 2 45 35 1 2 2 4.2 2 2 62 2 2 62 68 4.1.1 2 G 65 65 260 260 460 460
コンピュータと情報活用術
1 1 1. 20IT 2. 3. 4. 2 1.1 3 1.2 PC PC PC http//www. osakac. ac. jp/ihara/pdf 4 2 5 6 7 2.3.1 28 22 28 22 8 2.3.2 2228 9 No. 2 3 4 5 6 7 / / / / / 10 4M 11 12 13 14 2 15 3.1 16 17 18 19 3.5 3.7 20 2 3.8
説明書82：妊娠と抗てんかん薬★★.PPT
Preg-82 2002.8 Ⅰ. Nakane Y et al.: Multi-institutional study on the teratogenecity and fetal toxitity of antiepileptic drugs: A report of a collabolative study group in Japan. Epilepsia, 21; 663-680,1980.
13 3 21 11 60 11 3 10 13 3 21 11 3 10 38 11 7 23 1 11 11 12 39 12 2 29 2 12 3 15 40 12 8 30 3 12 11 2 41 13 2 20 4 13 3 15 42 13 3 15 10 14 16 1900 1945 1985 ( ) ( ) 1 2 6 2 Thiobacillus SO 2-4 H 2 S
54_2-05-地方会.indd
82 58 59 21 83 84 2 9 4 85 86 1. 87 6 88 89 β 1 90 2 3 p 4 t 5 6 EQ 91 7 8 9 1 10 2 92 11 3 12 13 IT p 14 93 15 16 ACTIVE 17 18 94 p p p 19 20 21 22 95 23 24 25 2 26 β β 96 27 1 28 29 30 97 31 32 33 1
「若年不安定就労・不安定住居者聞取り調査」報告書
2008 3 2006 2007 3 19 6 7 5,400 2007 4 5 19 94 1 2 2007 5 i 2007 6 12 100 100 1 2 2008 3 ii 1960 1990 iii = 1990 = = iv 5 5 v & = 2 24 = 1990 10 vi vii i iii 1 3 1.1.............................................